Lyra Therapeutics, Inc.
LYRA Healthcare Biotechnology
Lyra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $398,000.00, down 74.1% from fiscal 2024. In the quarter to December 2025, revenue fell 96.7%, EPS grew 53.0% and free cash flow grew 45.4%, each against the same quarter a year earlier.
Follow LYRA
Lyra Therapeutics, Inc. (LYRA) EV/Sales
As of 15 October 2026, Lyra Therapeutics, Inc. (LYRA) trades at a EV/Sales of −39.2×. Over the past ten years it has ranged from −42.0× (June 2024) to 186× (April 2024); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −27.9× | — |
| FY2024 | −17.7× | — |
| FY2023 | 100× | — |
| FY2022 | −3.3× | — |
| FY2021 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | −27.9× | — |
| Sep 2025 | −17.5× | — |
| Jun 2025 | −23.0× | — |
| Mar 2025 | −19.8× | — |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYRA Lyra Therapeutics, Inc. | −39.2× |
| MNTRQ 9 Meters Biopharma, Inc. compare | −0.5× |
| CRIS Curis, Inc. compare | −0.4× |
| BBLG Bone Biologics Corp. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | 0.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)